Navigation Links
High blood pressure, low energy -- a recipe for heart failure
Date:8/13/2007

Aug. 10, 2007 -- Many people with long-standing high blood pressure develop heart failure. But some don't. Daniel P. Kelly, M.D., and colleagues at Washington University School of Medicine in St. Louis and other institutions are trying to figure out what could explain that difference.

Their latest research reveals that impaired energy production in heart muscle may underlie heart failure in some hypertensive patients. The researchers assert that a molecular factor involved in maintaining the heart's energy supply could become a key to new approaches to prevent or treat heart failure.

The molecular factor, a protein called estrogen-related receptor alpha (ERR alpha), helps the heart keep up with energy-draining conditions like high blood pressure, which makes the heart work harder to pump blood. In the July issue of Cell Metabolism, Kelly and his colleagues report that mice born without any ERR alpha developed symptoms of heart failure when their hearts were forced to pump against high pressure. The hearts of normal mice took that pressure overload in stride and stayed healthy. Those contrasting outcomes suggest that heart health greatly depends on ERR alpha.

"The stress of a cardiac pressure overload asks heart muscle to manufacture more high energy compounds, and without ERR alpha, they can't do it," explains Kelly, the Tobias and Hortense Lewin Professor and Chief of the Cardiovascular Division. "You could say that in high blood pressure conditions, the heart fails because it becomes energy starved. And if you could feed the heart by using a drug that enhances ERR, for example you might enable the heart to better keep pace with its energy requirements."

Although preventions and treatments are now available for heart failure due to high blood pressure, almost all of those drugs act outside the heart by dilating blood vessels throughout the body to reduce resistance. In the future, doctors might look for diminished energy capacity in t
'/>"/>

Contact: Gwen Ericson
ericsong@wustl.edu
314-286-0141
Washington University School of Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. Placenta Is A Rich Source Of Blood Stem Cells
2. White blood cell waste disposal system plays critical regulatory role
3. Epstein-Barr virus protein crucial to its role in blood cancers
4. New insight into regulation of blood stem cells
5. Infants With Rare Genetic Disease Saved by Cord Blood Stem Cells
6. White Blood Cell Waste Disposal System Plays Critical Regulatory Role
7. Mystery Blood Vessel Disorder Implicated In Mini Strokes
8. Nano-bumps could help repair clogged blood vessels
9. First technology to remove prions that cause vCJD from blood launched
10. Infants with Rare Genetic Disease Saved By Cord Blood Stem Cells
11. Breakthrough isolating embryo-quality stem cells from blood
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 13, 2015 Technology Showcase, Hall E -   EyeLock ... today announced it will showcase its EyeLock ID technology integrated ... Department of Energy,s Oak Ridge National Laboratory (ORNL) ... EyeLock,s iris identity authentication technology is being used to validate ...
(Date:1/22/2015)... Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: NXTD and ... reports on the recent success of the Wocket™ smart wallet at CES ... smart wallet was named as one of the "11 Hot Products at ... Products Launched At CES So Far" by Newseveryday.com and "The top 10 ...
(Date:1/22/2015)... MUNICH , January 22, 2015 ... its tenth year  The European Patent Office to present ... Two British nominations to be featured: Christofer Toumazou ... week featuring former finalists and winners of the Award   ...
Breaking Biology News(10 mins):EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 2Ten Years of the European Inventor Award: A Retrospective Look at the Inventors and Ideas That Have Changed Our Lives 3
... or geophagy, has important health benefits for chimpanzees, ... the Musum National dHistoire Naturelle in Paris, France. ... has evolved as a practice for maintaining health ... to be published online this week in Springers ...
... at Childrens Hospital Boston have developed a new ... the cellular level. They describe the technology, which ... disease, in the January issue of Nature Nanotechnology ... PhD, and Robert Mannix, PhD, of Childrens program ...
... ANN ARBOR, Mich.---A device designed to eliminate mistakes made ... percent accurate in identifying the proper formulations of seven ... were averted over an 18-month period in a test ... Michigan Health System by using the technology, said Jim ...
Cached Biology News:Down to earth remedies for chimps 2An 'attractive' man-machine interface 2An 'attractive' man-machine interface 3Device prevents potential errors in children's medications 2
(Date:1/22/2015)... GEA Niro Soavi the leader in high pressure ... 2000, which is ideal for new applications for processing ... . This compact laboratory homogenizer is the perfect solution ... additives and ingredients as well as for the ...
(Date:1/22/2015)... (PRWEB) January 21, 2015 Cambridge Semantics, the ... technology, today announced that 2014 was a record-breaking year across ... capabilities of the Anzo Smart Data Platform and our Smart ... utilize insights from diverse data which led to record growth ...
(Date:1/22/2015)... Johnston, RI (PRWEB) January 22, 2015 ... State , The growing team of brand-neutral, independent consultants, ... CIO Philip Rogers explained that over the years, his ... including , Moroso, Town of Plainfield, as well as ...
(Date:1/22/2015)... Pipette.com has added the Eppendorf ... portfolio of Eppendorf products. , The Eppendorf Centrifuge 5424/5424 ... 5424/5424 R and receive the following:, , ... or Eppendorf Reference 2 ,     3 Free ...
Breaking Biology Technology:GEA Niro Soavi Announces the PandaPLUS 2000 Homogenizer for Processing New Applications for Nanoemulsions and Cell Disruption 2Cambridge Semantics Announces Record Results for 2014 2Protocol Networks Brings Independent Technology Consulting to the Constitution State 2Eppendorf Announces Promotional Bundle Which Includes: Eppendorf Centrifuge 5424, 3-Pack of Pipettes, and Tips - Available Now at Pipette.com 2
... Reduced the Size of Brain Tumors Associated ... with HER2-Positive Breast Cancer, ... from the extension arm of a Phase II study on ... this study of 49 patients, the combination of,TYKERB plus capecitabine ...
... ON, Dec. 17 /PRNewswire-FirstCall/ - Vasogen Inc.,(NASDAQ: VSGN ... a,confirmatory clinical trial which is designed to support ... System for the treatment of patients,with NYHA Class ... working diligently on the ACCLAIM-II study,including the establishment ...
... Dec. 17 SGX Pharmaceuticals, Inc.,(Nasdaq: SGXP ) ... to,the company,s Board of Directors. Mr. Turner brings over ... will also serve on,the company,s audit committee., "We ... Dr. Christopher S.,Henney, Chairman of the Board of Directors ...
Cached Biology Technology:GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases 2GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases 3GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases 4GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases 5GlaxoSmithKline Announces Data on TYKERB(R) (Lapatinib) Plus Capecitabine for the Treatment of HER2 Positive Breast Cancer Brain Metastases 6Vasogen Provides an Update on ACCLAIM-II Preparations 2Vasogen Provides an Update on ACCLAIM-II Preparations 3Vasogen Provides an Update on ACCLAIM-II Preparations 4SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors 2SGX Pharmaceuticals Appoints Joseph L. Turner to Board of Directors 3
muscle actin (HUC1-1)...
Anti-Mouse MIP-1g, Biotin (Polyclonal) (rabbit IgG)...
... E978 GenBank Accession ... Immunogen : NY-ESO-1 full-length ... ascites with 0.05% sodium ... evaluated by immunoblot on ...
... Opsin 1 ( Abpromise for all tested ... YEDSTHASIFTYT, corresponding to amino acids 14/26 of Mouse ... to amino acids 18/30 of tiger red cones ... Entrez Gene ID: 5956 ...
Biology Products: